Somatopause, which occurs in the 30s, is an event where growth hormone production dramatically decreases, and replacing growth hormone to address somatopause is a debated topic in the medical community 6m6s
Lancet 389 , 12381252 (2017)
Peptides newly approved for compounding (such as BPC-157, KPV, and TB-500) have only been evaluated for specific use cases
Many patients and providers opt for ongoing therapy, especially at low maintenance doses
Researchers have studied 5-Amino-1MQ as an NNMT inhibitor due to growing evidence suggesting that NNMT may influence adipose tissue biology, energy expenditure, glucose metabolism, and cellular metabolic regulation
This is one of the cleaner pharmacokinetic profiles you will find among GLP-1 receptor agonists